101. Update on advances in molecular PET in urological oncology
- Author
-
Shingo Yamamoto, Takao Kamai, Kazuhito Fukushima, Ryogo Minamimoto, Kazuhiro Kitajima, and Hossein Jadvar
- Subjects
Male ,Urologic Neoplasms ,medicine.medical_specialty ,medicine.medical_treatment ,Malignancy ,Multimodal Imaging ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Fluorodeoxyglucose F18 ,Positron Emission Tomography Computed Tomography ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Urinary Tract ,Bladder cancer ,medicine.diagnostic_test ,business.industry ,Magnetic resonance imaging ,medicine.disease ,Magnetic Resonance Imaging ,Radiation therapy ,Positron emission tomography ,Positron-Emission Tomography ,030220 oncology & carcinogenesis ,Female ,Radiology ,Radiopharmaceuticals ,business ,Nuclear medicine ,Kidney cancer ,Preclinical imaging - Abstract
Integrated positron emission tomography/computed tomography (PET/CT) with 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) has emerged as a powerful tool for the combined metabolic and anatomic evaluation of many cancers. In urological oncology, however, the use of (18)F-FDG has been limited by a generally low tumor uptake, and physiological excretion of FDG through the urinary system. (18)F-FDG PET/CT is useful when applied to specific indications in selected patients with urological malignancy. New radiotracers and positron emission tomography/magnetic resonance imaging (PET/MRI) are expected to further improve the performance of PET in uro-oncology.
- Published
- 2016
- Full Text
- View/download PDF